Endometrial Cancer - PMC
While endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy.
While endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy. This comprehensive review will provide an update on the epidemiology, pathophysiology, diagnosis and molecular classification, recent advancements in disease management, as well important patient quality of life considerations and emerging developments in the rapidly evolving therapeutic landscape of endometrial cancers.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Immunotherapy improves endometrial cancer outcomes
- Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials
- Current recommendations and recent progress in endometrial cancer
- Advancements in Endometrial Cancer Research in 2024
- Selinexor Maintenance Improves PFS in TP53 Wild-Type Endometrial Cancer